Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis



Rating:

Share or cite this content

Citations should be made in the following way:
R. Usmanova (Tashkent, Uzbekistan), N. Parpieva (Tashkent, Uzbekistan), I. Liverko (Tashkent, Uzbekistan), H. Davtyan (Nor Hachn, Ukraine), O. Danisiuk (Kyiv, Ukraine), A. Kumar (Paris, France), J. Gadoev (Tashkent, Uzbekistan), S. Alaverdyan (Bielefeld, Germany), K. Dumchev (Kyiv, Ukraine), B. Abdusamatova (Tashkent, Uzbekistan), I. Butabekov (Tashkent, Uzbekistan). Treatment of multidrug-resistant tuberculosis in Uzbekistan from 2012 to 2018: does practice follow policy?. 3333

Member's Comments

No comment yet.

Related content which might interest you: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 TB and MDR-TB: what is new in 2012? Source: Breathe 2012; 9: 100-111 Year: 2012 National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Indicators of rifampicin-resistant TB response in Belarus, 2009-2014 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 The global response to rifampicin-resistant tuberculosis: Current situation and recent trends Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Management of tuberculosis (TB) at a district general hospital: An audit of practice Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013 High initial multidrug-resistant tuberculosis rate in Buenaventura, Colombia: a public–private initiative Source: Eur Respir J 2012; 40: 1569-1572 Year: 2012 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice Source: Eur Respir J 2016; 48: 1571-1581 Year: 2016 Variation in policy and practice of adolescent tuberculosis management in the WHO European Region Source: Eur Respir J 2016; 48: 943-946 Year: 2016 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Cross-border management of tuberculosis cases through an updated ERS/WHO TB consilium Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement Source: Eur Respir J 2012; 40: 1081-1090 Year: 2012 Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care Source: Eur Respir J 2016; 48: 1278-1281 Year: 2016 Treatment outcomes in patients with multidrug-resistant tuberculosis in Japan, 2011-2013 Source: International Congress 2017 – MDRTB: detection and management Year: 2017 The health economics of treating MDR-TB in the Indian private sector Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016